SJEPD030930_D1.RNA-Seq
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- age_years
- 5.87
- e1_e2
- E2
- umap1_2d
- -6.886521289
- umap2_2d
- 1.50003163
- umap1_3d
- -0.150082793
- umap2_3d
- 4.645531638
- umap3_3d
- 0.100736434
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.600
- OXIDATIVE_PHOSPHORYLATION+0.490
- MYC_TARGETS_V1+0.440
- MTORC1_SIGNALING+0.360
- ANDROGEN_RESPONSE+0.330
- FATTY_ACID_METABOLISM+0.330
- PEROXISOME+0.280
- ADIPOGENESIS+0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.260
- UV_RESPONSE_DN+0.260
Top 10 suppressed
- APICAL_SURFACE-0.390
- TNFA_SIGNALING_VIA_NFKB-0.380
- WNT_BETA_CATENIN_SIGNALING-0.380
- PANCREAS_BETA_CELLS-0.370
- IL6_JAK_STAT3_SIGNALING-0.280
- INTERFERON_ALPHA_RESPONSE-0.280
- KRAS_SIGNALING_DN-0.280
- INFLAMMATORY_RESPONSE-0.270
- ANGIOGENESIS-0.260
- APICAL_JUNCTION-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030060_D1.RNA-Seq | EPN | EPN Tumor | 0.843 |
| 2 | SJEPD030784_D1.RNA-Seq | EPN | Myxopapillary EPN | 0.837 |
| 3 | R125 | — | — | 0.821 |
| 4 | MNG241 | — | — | 0.819 |
| 5 | BS_WYERXS4G | Supratentorial Ependymoma | — | 0.818 |
| 6 | R414 | — | — | 0.814 |
| 7 | 9cdb8246-eedc-40e2-b340-52db1edd0838 | — | — | 0.807 |
| 8 | MNG1022 | — | — | 0.805 |
| 9 | BS_KVAJYZ6F | Glial-neuronal tumor NOS | — | 0.801 |
| 10 | BS_KSKZ9J7J | Embryonal tumors | — | 0.799 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.600 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.490 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| PEROXISOME | 0.280 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.070 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |